A new study presented at the American Society of Hematology (ASH) annual meeting examines the implications of a polygenic score called ACS10 for Black pediatric patients with acute myeloid leukemia (AML). This score can predict patients’ response to cytarabine based on their genetic makeup and may help personalize treatment for Black pediatric patients with AML, who typically experience worse outcomes than White patients. The study found that the ACS10 score is significantly linked to the outcomes of Black patients, and patients with low scores have worse outcomes when initially treated with low-dose cytarabine. The analysis suggests that physicians should consider genetic differences in tailoring treatment to improve outcomes for Black patients with AML.
Source link
This Test May Guide AML Therapy for Black Pediatric Patients
